--- title: "uniQure (QURE) news: offering" url: "https://aibio.space/companies/uniqure-n-v/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "QURE offering news: uniQure launches $150,000,000 offering, then prices an upsized $225 million sale. uniQure N.V. (NASDAQ: QURE), Netherlands." --- QURE uniQure N.V. NASDAQ · Netherlands # uniQure (QURE) news QURE offering news Financings · 2026-06-22 ## [uniQure launches $150,000,000 offering, then prices an upsized $225 million sale](https://aibio.space/news/uniqure-launches-150-000-000-offering-then-prices-upsized-225-million/) uniQure filed a $150,000,000 offering on June 22, 2026 and priced an upsized deal on June 23. The FDA has said its Huntington's data are not sufficient evidence for a marketing application, and the proceeds are partly earmarked for a launch. ## Latest uniQure news 1. 2025-09-24 Debt Financing [uniQure amends Hercules term loan and draws $50 million to refinance debt](https://aibio.space/news/uniqure-amends-hercules-term-loan-draws-50-million-refinance-debt/) uniQure amended its Hercules term loan on September 22, 2025. The 2025 Term Loan is up to $175 million, $50 million was drawn at closing to refinance existing debt, and the balance depends on milestones tied to AMT-130. ## uniQure at a glance - **Ticker**: QURE - **Listing**: NASDAQ - **Country**: Netherlands - **Cash, Mar 31, 2026**: $140.0 million ### Related companies - [argenx](https://aibio.space/companies/argenx/) EURONEXT: ARGX - [Pharvaris](https://aibio.space/companies/pharvaris-n-v/) NASDAQ: PHVS - [NewAmsterdam Pharma Company](https://aibio.space/companies/newamsterdam-pharma-n-v/) NASDAQ: NAMS - [ProQR Therapeutics](https://aibio.space/companies/proqr-therapeutics-n-v/) NASDAQ: PRQR - [Pharming Group NV](https://aibio.space/companies/pharming/) EURONEXT: PHARM ### Also on NASDAQ - [Structure Therapeutics](https://aibio.space/companies/structure-therapeutics/) GPCR - [MetaVia](https://aibio.space/companies/metavia/) MTVA - [Advanced Biomed](https://aibio.space/companies/advanced-biomed/) ADVB - [SS Innovations International](https://aibio.space/companies/ss-innovations-international/) SSII - [Edesa Biotech](https://aibio.space/companies/edesa-biotech/) EDSA - [BridgeBio Pharma](https://aibio.space/companies/bridgebio-pharma/) BBIO ## uniQure annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$140.7 million](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/) | [$143.8 million](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/) | | Net income (loss) | [-$199.0 million](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/) | [-$239.6 million](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/) | | Cash from operations | [-$178.0 million](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/) | [-$182.7 million](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/) | | Cash and equivalents | [$80.2 million](https://www.sec.gov/Archives/edgar/data/1590560/000110465926055250/) | [$158.9 million](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/) | Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $140.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about uniQure Has uniQure raised money recently? Our latest story on this, dated Jun 22, 2026: "uniQure launches $150,000,000 offering, then prices an upsized $225 million sale". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/uniqure-launches-150-000-000-offering-then-prices-upsized-225-million/). What is the ticker symbol of uniQure? uniQure N.V. trades under the ticker QURE on NASDAQ. Where is uniQure listed? uniQure N.V. is listed on NASDAQ. Our directory also records these other listings: BMV:QURE/N; FWB:UQ1; GETTEX:UQ1; HAM:UQ1; HAN:UQ1; LS:A1XDTV; LSE:0EE0; LSX:A1XDTV; SWB:UQ1; TRADEGATE:UQ1; XETR:UQ1. What is the SEC CIK of uniQure? The SEC Central Index Key (CIK) for uniQure N.V. is 1590560. Its filings are on SEC EDGAR. Which country or territory is uniQure listed under? Our directory records uniQure N.V. under Netherlands. What does uniQure do? Our directory classifies uniQure N.V. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of uniQure? The ISIN recorded for uniQure N.V. is NL0010696654. Does aibio.space cover uniQure? aibio.space lists uniQure N.V. among 2,820 public biotech companies and publishes its news here as stories appear. Is uniQure profitable? uniQure N.V. reported a net loss of $199.0 million for the fiscal year ended Dec 31, 2025, and used $178.0 million of cash in operations, per its annual report to the SEC. How much does uniQure spend on research and development? $140.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does uniQure have? $140.0 million in cash at Mar 31, 2026, per its 10-Q. What is the latest uniQure (QURE) stock news? Our latest story on uniQure, dated Jun 22, 2026: "uniQure launches $150,000,000 offering, then prices an upsized $225 million sale". uniQure filed a $150,000,000 offering on June 22, 2026 and priced an upsized deal on June 23. The FDA has said its Huntington's data are not sufficient evidence for a marketing application, and the proceeds are partly earmarked for a launch. [Source](https://aibio.space/news/uniqure-launches-150-000-000-offering-then-prices-upsized-225-million/). Does uniQure have debt, a term loan or convertible notes? Our latest debt story, dated Sep 24, 2025: "uniQure amends Hercules term loan and draws $50 million to refinance debt". uniQure amended its Hercules term loan on September 22, 2025. The 2025 Term Loan is up to $175 million, $50 million was drawn at closing to refinance existing debt, and the balance depends on milestones tied to AMT-130. [Source](https://aibio.space/news/uniqure-amends-hercules-term-loan-draws-50-million-refinance-debt/). How long will uniQure's cash last? From our story of Sep 24, 2025: The 10-K, written before this loan amendment, says net proceeds from a follow-on share offering that raised $70.1 million, together with existing cash, cash equivalents and investments, will fund operations into the second half of 2027. [Source](https://aibio.space/news/uniqure-amends-hercules-term-loan-draws-50-million-refinance-debt/). What is uniQure's market cap? We do not publish live share prices. In its annual report, uniQure N.V. put the market value of shares held by non-affiliates (public float) at $764.8 million as of Jun 30, 2025. ## Investor discussion: uniQure Members talk about uniQure (QURE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at uniQure, newest first. Each line links the filing it comes from. 1. 2026-06-22 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1590560/000110465926076466/tm2618428-1_424b5.htm) 2. 2026-03-02 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm) 3. 2025-09-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1590560/000110465925092995/tm2526258-1_424b5.htm) 4. 2025-07-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1590560/000110465925071438/tm2521648-1_424b5.htm) 5. 2025-01-07 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1590560/000110465925001728/tm251946-3_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:QURE on TradingView](https://www.tradingview.com/symbols/NASDAQ-QURE/). ## SEC filings and registration - **SEC name**: uniQure N.V. - **CIK**: 1590560 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: QURE (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: PAASHEUVELWEG 25A, AMSTERDAM, 1105 BP - **Phone**: 1-339-970-7000 - **Former names**: uniQure B.V. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465926111654/tm2626514d1_8k.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465926104463/qure-20260902x8k.htm) filed 2026-09-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1590560/000110465926087815/qure-20260630x10q.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/qure-20260729x8k.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465926077339/tm2618105d1_8k.htm) filed 2026-06-24 - [424B5](https://www.sec.gov/Archives/edgar/data/1590560/000110465926077336/tm2618428-2_424b5.htm) filed 2026-06-24 - [424B5](https://www.sec.gov/Archives/edgar/data/1590560/000110465926076466/tm2618428-1_424b5.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465926076044/qure-20260619x8k.htm) filed 2026-06-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001590560), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details uniQure N.V. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker QURE, recorded under Netherlands. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: uniQure N.V. - **Ticker**: QURE - **Listing**: NASDAQ - **Country or territory**: Netherlands - **Business scope**: Biotechnology - **ISIN**: NL0010696654 - **Other listed symbols**: BMV:QURE/N; FWB:UQ1; GETTEX:UQ1; HAM:UQ1; HAN:UQ1; LS:A1XDTV; LSE:0EE0; LSX:A1XDTV; SWB:UQ1; TRADEGATE:UQ1; XETR:UQ1 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-QURE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/uniqure-n-v/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "uniQure (QURE) news: offering", 2026-10-31, https://aibio.space/companies/uniqure-n-v/